The inflammatory diseases ulcerative colitis and Crohn's disease constitute the two main
forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing …

Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small
molecules that have expanded the therapeutic options for the management of chronic …

Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn's disease, are
chronic, immune-mediated and progressive inflammatory disorders affecting the …

Although development of biologics has importantly improved the effectiveness in inducing
and maintaining remission in inflammatory bowel disease (IBD), biologic therapies still have …

Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling
conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract …

Abstract Background and Aims Many inflammatory bowel disease (IBD) patients do not
respond to medical therapy. Tofacitinib is a first-in-class, partially selective inhibitor of Janus …

The two major forms of inflammatory bowel disease (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic immune-mediated conditions characterised by …

Abstract Background Janus kinases (JAKs) mediate cytokine signaling involved in
inflammatory bowel disease. The pan-JAK inhibitor tofacitinib has shown efficacy in the …